GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

GlaxoSmithKline ( GSK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.4%. By the end of trading, GlaxoSmithKline rose $0.56 (1.1%) to $53.22 on average volume. Throughout the day, 3,416,236 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2,373,600 shares. The stock ranged in a price between $52.86-$53.22 after having opened the day at $52.96 as compared to the previous trading day's close of $52.66. Other companies within the Health Care sector that increased today were: CombiMatrix Corporation ( CBMX), up 36.3%, Cardiome Pharma Corporation ( CRME), up 19.7%, Hooper Holmes ( HH), up 15.2% and Fonar Corporation ( FONR), up 14.9%.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $127.9 billion and is part of the drugs industry. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7. Shares are up 21.1% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 38.1%, Oncolytics Biotech ( ONCY), down 23.8%, IntelliPharmaCeutics International ( IPCI), down 11.4% and Can Fite Biofarma Ltd. ADR ( CANF), down 11.0% , were all laggards within the health care sector with Catamaran ( CTRX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment